Synuclein activates microglia in a model of Parkinson's disease

Neurobiology of Aging

Volumn 29, Issue 11, 2008, Pages 1690-1701

  Su, Xiaomin ^a   Maguire Zeiss, Kathleen A ^a   Giuliano, Rita ^a   Prifti, Landa ^a   Venkatesh, Karthik ^a   Federoff, Howard J ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

CD36; Microglia; MN9D; Parkinson's disease; Proinflammatory cytokines; Synuclein

Indexed keywords

LIPOPOLYSACCHARIDE; PROTEIN KINASE; RECOMBINANT SYNUCLEIN; SCAVENGER RECEPTOR; SYNUCLEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; EARLY DIAGNOSIS; GENE OVEREXPRESSION; INFLAMMATION; LEWY BODY; MICROGLIA; MOLECULAR MODEL; MOTOR DYSFUNCTION; MOUSE; NEWBORN; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; SUBSTANTIA NIGRA; UNITED STATES; WILD TYPE;

ANIMALS; CELL LINE; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROGLIA; PARKINSONIAN DISORDERS; SYNUCLEINS;

EID: 51449099473     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2007.04.006     Document Type: Article

References (84)

1. Abbas N., Lucking C.B., Ricard S., Durr A., Bonifati V., De Michele G., Bouley S., Vaughan J.R., Gasser T., Marconi R., Broussolle E., Brefel-Courbon C., Harhangi B.S., Oostra B.A., Fabrizio E., Bohme G.A., Pradier L., Wood N.W., Filla A., Meco G., Denefle P., Agid Y., and Brice A. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's disease. Hum. Mol. Genet. 8 (1999) 567-574
2. Ali S.F., David S.N., and Newport G.D. Age-related susceptibility to MPTP-induced neurotoxicity in mice. Neurotoxicology 14 (1993) 29-34
3. Ancolio K., Alves da Costa C., Ueda K., and Checler F. Alph-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells. Neurosci. Lett. 285 (2000) 79-82
4. Baba M., Nakajo S., Tu P.H., Tomita T., Nakaya K., Lee V.M., Trojanowski J.Q., and Iwatsubo T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152 (1998) 879-884
5. Bamberger M.E., Harris M.E., McDonald D.R., Husemann J., and Landreth G.E. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J. Neurosci. 23 (2003) 2665-2674
6. Bankiewicz K.S., Plunkett R.J., Jacobowitz D.M., Porrino L., di Porzio U., London W.T., Kopin I.J., and Oldfield E.H. The effect of fetal mesencephalon implants on primate MPTP-induced parkinsonism. Histochemical and behavioral studies. J. Neurosurg. 72 (1990) 231-244
7. Beal M.F. Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2 (2001) 325-334
8. Block M.L., Zecca L., and Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8 (2007) 57-69
9. Borghi R., Marchese R., Negro A., Marinelli L., Forloni G., Zaccheo D., Abbruzzese G., and Tabaton M. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci. Lett. 287 (2000) 65-67
10. Campbell A. Inflammation, neurodegenerative diseases, and environmental exposures. Ann. N.Y. Acad. Sci. 1035 (2004) 117-132
11. Coraci I.S., Husemann J., Berman J.W., Hulette C., Dufour J.H., Campanella G.K., Luster A.D., Silverstein S.C., and El-Khoury J.B. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am. J. Pathol. 160 (2002) 101-112
12. Croisier E., Moran L.B., Dexter D.T., Pearce R.K., and Graeber M.B. Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J. Neuroinflamm. 2 (2005) 14
13. Dong Z., Ferger B., Feldon J., and Bueler H. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP. J. Neurobiol. 53 (2002) 1-10
14. Duvoisin R.C. Overview of Parkinson's disease. Ann. N.Y. Acad. Sci. 648 (1992) 187-193
15. El Khoury J.B., Moore K.J., Means T.K., Leung J., Terada K., Toft M., Freeman M.W., and Luster A.D. CD36 mediates the innate host response to beta-amyloid. J. Exp. Med. 197 (2003) 1657-1666
16. El-Agnaf O.M., Salem S.A., Paleologou K.E., Cooper L.J., Fullwood N.J., Gibson M.J., Curran M.D., Court J.A., Mann D.M., Ikeda S., Cookson M.R., Hardy J., and Allsop D. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 77 (2003) 1945-1947
17. Fortin D.L., Nemani V.M., Voglmaier S.M., Anthony M.D., Ryan T.A., and Edwards R.H. Neural activity controls the synaptic accumulation of alpha-synuclein. J. Neurosci. 25 (2005) 10913-10921
18. Giasson B.I., Uryu K., Trojanowski J.Q., and Lee V.M. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274 (1999) 7619-7622
19. Gomez-Santos C., Ferrer I., Reiriz J., Vinals F., Barrachina M., and Ambrosio S. MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. Brain Res. 935 (2002) 32-39
20. Hashimoto M., Rockenstein E., and Masliah E. Transgenic models of alpha-synuclein pathology: past, present, and future. Ann. N.Y. Acad. Sci. 991 (2003) 171-188
21. Heller A., Freeney A., Hessefort S., Villereal M., and Won L. Cellular dopamine is increased following exposure to a factor derived from immortalized striatal neurons in humans. Neurosci. Lett. 295 (2000) 1-4
22. Heller A., Price S., and Won L. Glial-derived neurotrophic factor (GDNF) induced morphological differentiation of an immortalized monoclonal hybrid dopaminergic cell line of mesencephalic neuronal origin. Brain Res. 725 (1996) 132-136
23. Hirsch E.C., Hunot S., and Hartmann A. Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat. Disord. 11 Suppl. 1 (2005) S9-S15
24. Ho G.J., Drego R., Hakimian E., and Masliah E. Mechanisms of cell signaling and inflammation in Alzheimer's disease. Curr. Drug Targets Inflamm. Allergy 4 (2005) 247-256
25. Husemann J., Loike J.D., Anankov R., Febbraio M., and Silverstein S.C. Scavenger receptors in neurobiology and neuropathology: their role on microglia and other cells of the nervous system. Glia 40 (2002) 195-205
26. Husemann J., Loike J.D., Kodama T., and Silverstein S.C. Scavenger receptor class B type I (SR-BI) mediates adhesion of neonatal murine microglia to fibrillar beta-amyloid. J. Neuroimmunol. 114 (2001) 142-150
27. Irizarry M.C., Growdon W., Gomez-Isla T., Newell K., George J.M., Clayton D.F., and Hyman B.T. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J. Neuropathol. Exp. Neurol. 57 (1998) 334-337
28. Kahle P.J., Neumann M., Ozmen L., Muller V., Jacobsen H., Schindzielorz A., Okochi M., Leimer U., van Der Putten H., Probst A., Kremmer E., Kretzschmar H.A., and Haass C. Subcellular localization of wild-type and Parkinson's disease- associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci. 20 (2000) 6365-6373
29. Kim Y.S., and Joh T.H. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp. Mol. Med. 38 (2006) 333-347
30. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., and Shimizu N. Mutations in the Parkin gene cause autosomal recessive juvenile Parkinsonism. Nature 392 (1998) 605-608
31. Kitada T., Asakawa S., Matsumine H., Hattori N., Shimura H., Minoshima S., Shimizu N., and Mizuno Y. Progress in the clinical and molecular genetics of familial Parkinsonism. Neurogenetics 2 (2000) 207-218
32. Klegeris A., Pelech S., Giasson B.I., Maguire J., Zhang H., McGeer E.G., and McGeer P.L. alpha-Synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol. Aging (2006)
33. Knott C., Stern G., and Wilkin G.P. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol. Cell Neurosci. 16 (2000) 724-739
34. Kohutnicka M., Lewandowska E., Kurkowska-Jastrzebska I., Czlonkowski A., and Czlonkowska A. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 39 (1998) 167-180
35. Kowall N.W., Hantraye P., Brouillet E., Beal M.F., McKee A.C., and Ferrante R.J. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 77 (2000) 211-213
36. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19 (1996) 312-318
37. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., and Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18 (1998) 106-108
38. Kunjathoor V.V., Tseng A.A., Medeiros L.A., Khan T., and Moore K.J. beta-Amyloid promotes accumulation of lipid peroxides by inhibiting CD36-mediated clearance of oxidized lipoproteins. J. Neuroinflamm. 1 (2004) 23
39. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
40. Langston J.W., Irwin I., Langston E.B., and Forno L.S. 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci. Lett. 48 (1984) 87-92
41. Langston J.W., Langston E.B., and Irwin I. MPTP-induced parkinsonism in human and non-human primates-clinical and experimental aspects. Acta Neurol. Scand. Suppl. 100 (1984) 49-54
42. Lee H.J., Patel S., and Lee S.J. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J. Neurosci. 25 (2005) 6016-6024
43. Lee M.K., Stirling W., Xu Y., Xu X., Qui D., Mandir A.S., Dawson T.M., Copeland N.G., Jenkins N.A., and Price D.L. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 8968-8973
44. Liu B., and Hong J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 304 (2003) 1-7
45. Maguire-Zeiss K.A., and Federoff H.J. Convergent pathobiologic model of Parkinson's disease. Ann. N.Y. Acad. Sci. 991 (2003) 152-166
46. Maguire-Zeiss K.A., Wang C.I., Yehling E., Sullivan M.A., Short D.W., Su X., Gouzer G., Henricksen L.A., Wuertzer C.A., and Federoff H.J. Identification of human alpha-synuclein specific single chain antibodies. Biochem. Biophys. Res. Commun. 349 (2006) 1198-1205
47. Manning-Bog A.B., McCormack A.L., Li J., Uversky V.N., Fink A.L., and Di Monte D.A. The herbicide paraquat causes upregulation and aggregation of alpha-synuclein in mice. J. Biol. Chem. 13 (2001) 13
48. Manning-Bog A.B., McCormack A.L., Li J., Uversky V.N., Fink A.L., and Di Monte D.A. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem. 277 (2002) 1641-1644
49. Maroteaux L., Campanelli J.T., and Scheller R.H. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8 (1988) 2804-2815
50. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., and Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287 (2000) 1265-1269
51. Matsuoka Y., Vila M., Lincoln S., McCormack A., Picciano M., LaFrancois J., Yu X., Dickson D., Langston W.J., McGowan E., Farrer M., Hardy J., Duff K., Przedborski S., and Di Monte D.A. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 8 (2001) 535-539
52. McGeer E.G., Klegeris A., and McGeer P.L. Inflammation, the complement system and the diseases of aging. Neurobiol. Aging 26 Suppl 1 (2005) 94-97
53. McGeer P.L., Itagaki S., Boyes B.E., and McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988) 1285-1291
54. McGeer P.L., and McGeer E.G. Inflammation and the degenerative diseases of aging. Ann. N.Y. Acad. Sci. 1035 (2004) 104-116
55. Medeiros L.A., Khan T., El Khoury J.B., Pham C.L., Hatters D.M., Howlett G.J., Lopez R., O'Brien K.D., and Moore K.J. Fibrillar amyloid protein present in atheroma activates CD36 signal transduction. J. Biol. Chem. 279 (2004) 10643-10648
56. Mezey E., Dehejia A.M., Harta G., Tresser N., Suchy S.F., Nussbaum R.L., Brownstein M.J., and Polymeropoulos M.H. Alpha synuclein is present in Lewy bodies in sporadic Parkinson's disease. Mol. Psychiatry 3 (1998) 493-499
57. Miller R.M., Callahan L.M., Casaceli C., Chen L., Kiser G.L., Chui B., Kaysser-Kranich T.M., Sendera T.J., Palaniappan C., and Federoff H.J. Dysregulation of gene expression in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse substantia nigra. J. Neurosci. 24 (2004) 7445-7454
58. Moore K.J., El Khoury J., Medeiros L.A., Terada K., Geula C., Luster A.D., and Freeman M.W. A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J. Biol. Chem. 277 (2002) 47373-47379
59. Peyrin J.M., Lasmezas C.I., Haik S., Tagliavini F., Salmona M., Williams A., Richie D., Deslys J.P., and Dormont D. Microglial cells respond to amyloidogenic PrP peptide by the production of inflammatory cytokines. Neuroreport 10 (1999) 723-729
60. Polymeropoulos M.H. Genetics of Parkinson's disease. Ann. N.Y. Acad. Sci. 920 (2000) 28-32
61. Polymeropoulos M.H., Higgins J.J., Golbe L.I., Johnson W.G., Ide S.E., Di Iorio G., Sanges G., Stenroos E.S., Pho L.T., Schaffer A.A., Lazzarini A.M., Nussbaum R.L., and Duvoisin R.C. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 274 (1996) 1197-1199
62. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., and Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
63. Przedborski S., Chen Q., Vila M., Giasson B.I., Djaldatti R., Vukosavic S., Souza J.M., Jackson-Lewis V.V., Lee V.M., and Ischiropoulos H. Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J. Neurochem. 76 (2001) 637-640
64. Przedborski S., Jackson-Lewis V., Naini A.B., Jakowec M., Petzinger G., Miller R., and Akram M. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem. 76 (2001) 1265-1274
65. Rathke-Hartlieb S., Kahle P.J., Neumann M., Ozmen L., Haid S., Okochi M., Haass C., and Schulz J.B. Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice. J. Neurochem. 77 (2001) 1181-1184
66. Richfield E.K., Thiruchelvam M.J., Cory-Slechta D.A., Wuertzer C., Gainetdinov R.R., Caron M.G., Di Monte D.A., and Federoff H.J. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp. Neurol. 175 (2002) 35-48
67. Schmidt N., and Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. J. Neural Transm. 108 (2001) 1263-1282
68. Seniuk N.A., Tatton W.G., and Greenwood C.E. Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res. 527 (1990) 7-20
69. Serpell L.C., Berriman J., Jakes R., Goedert M., and Crowther R.A. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 4897-4902
70. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., and Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302 (2003) 841
71. Song D.D., Shults C.W., Sisk A., Rockenstein E., and Masliah E. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp. Neurol. 186 (2004) 158-172
72. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., and Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 6469-6473
73. Strathdee C.A., McLeod M.R., and Hall J.R. Efficient control of tetracycline-responsive gene expression from an autoregulated bi-directional expression vector. Gene 229 (1999) 21-29
74. Sung J.Y., Park S.M., Lee C.H., Um J.W., Lee H.J., Kim J., Oh Y.J., Lee S.T., Paik S.R., and Chung K.C. Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases. J. Biol. Chem. 280 (2005) 25216-25224
75. Sveinbjornsdottir S., Hicks A.A., Jonsson T., Petursson H., Gugmundsson G., Frigge M.L., Kong A., Gulcher J.R., and Stefansson K. Familial aggregation of Parkinson's disease in Iceland. N. Engl. J. Med. 343 (2000) 1765-1770
76. Tabrizi S.J., Orth M., Wilkinson J.M., Taanman J.W., Warner T.T., Cooper J.M., and Schapira A.H. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum. Mol. Genet. 9 (2000) 2683-2689
77. Tatton N.A., and Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77 (1997) 1037-1048
78. Thiruchelvam M.J., Powers J.M., Cory-Slechta D.A., and Richfield E.K. Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice. Eur. J. Neurosci. 19 (2004) 845-854
79. Thomas D.M., Walker P.D., Benjamins J.A., Geddes T.J., and Kuhn D.M. Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J. Pharmacol. Exp. Ther. 311 (2004) 1-7
80. van der Putten H., Wiederhold K.H., Probst A., Barbieri S., Mistl C., Danner S., Kauffmann S., Hofele K., Spooren W.P., Ruegg M.A., Lin S., Caroni P., Sommer B., Tolnay M., and Bilbe G. Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20 (2000) 6021-6029
81. Varastet M., Riche D., Maziere M., and Hantraye P. Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease. Neuroscience 63 (1994) 47-56
82. Verdier Y., and Penke B. Binding sites of amyloid beta-peptide in cell plasma membrane and implications for Alzheimer's disease. Curr. Protein Pept. Sci. 5 (2004) 19-31
83. Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowec M., and Przedborski S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 74 (2000) 721-729
84. Zhang W., Wang T., Pei Z., Miller D.S., Wu X., Block M.L., Wilson B., Zhang W., Zhou Y., Hong J.S., and Zhang J. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 19 (2005) 533-542